1. "Head and Neck Service"
Formats
  1. Journal Article (407)
  2. Meeting Abstract (360)
  3. Book Section (20)
  4. Review (19)
  5. Editorial (7)
  6. Guidelines (7)
  7. Research Letter (6)
  8. Correspondence (3)
  9. Book Whole (1)
  10. Conference Paper (1)
  11. Miscellaneous (1)
Groups
  1. Head and Neck Service (832)
  2. Solid Tumor Oncology Division (832)
  3. Department of Medicine (826)
  4. Surgery (358)
  5. Radiation Oncology, Department of (310)
  6. Survivorship Research (310)

More Groups

People
  1. David Pfister (389)
  2. Eric Sherman (339)
  3. Nancy Lee (266)
  4. Alan Ho (238)
  5. Nadeem Riaz (159)
  6. Lara Dunn (141)

More People

Years
  1. 2025 (12)
  2. 2024 (72)
  3. 2023 (55)
  4. 2022 (57)
  5. 2021 (58)
  6. 2020 (66)

More Years

Publications
  1. Journal of Clinical Oncology (205)
  2. International Journal of Radiation Oncology, Biology, Physics (140)
  3. Annals of Oncology (43)
  4. Cancer (33)
  5. Head & Neck (28)
  6. Journal of the National Comprehensive Cancer Network (28)

More Publications

Publishers
  1. American Society of Clinical Oncology (219)
  2. Elsevier Inc. (176)
  3. Wiley Blackwell (55)
  4. Oxford University Press (53)
  5. American Association for Cancer Research (46)
  6. Harborside Press (28)

More Publishers

Results (832)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma
    Journal Article

    McBride, S.; Sherman, E.; Tsai, C. J.; Baxi, S.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D.; Michel, L. S.; Young, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers
    Journal Article

    Jhaveri, K.; Chang, M. T.; Juric, D.; Saura, C.; Gambardella, V.; Melnyk, A.; Patel, M. R.; Ribrag, V.; Ma, C. X.; Aljumaily, R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Case study of the integration of electronic patient-reported outcomes as standard of care in a head and neck oncology practice: Obstacles and opportunities
    Journal Article

    Strachna, O.; Cohen, M. A.; Allison, M. M.; Pfister, D. G.; Lee, N. Y.; Wong, R. J.; McBride, S. M.; Mohammed, R. R.; Kemeny, E.; Polubriaginof, F. C. G.; more...
    Cancer (2021)

    Fulltext@MSK | Save
  • Trends in chronic opioid therapy among survivors of head and neck cancer
    Journal Article

    Kriplani, A.; Lavery, J. A.; Mishra, A.; Korenstein, D.; Lipitz-Snyderman, A. N.; Boudreau, D. M.; Moryl, N.; Gillespie, E. F.; Salz, T.
    Head & Neck (2021)

    Fulltext@MSK | Save
  • TROPiCS-03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors
    Meeting Abstract

    Saxena, A.; Michel, L. S.; Hong, Q.; Hilsinger, K.; Kanwal, C.; Pichardo, C.; Goswami, T.; Santin, A.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma
    Meeting Abstract

    Kang, H.; Ho, A. L.; Muzaffar, J.; Bowles, D. W.; Kim, S. B.; Ahn, M. J.; Hanna, G. J.; Worden, F. P.; Yun, T.; Norton, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with HRAS mutations (AIM-HN) and the impact of HRAS mutations on response to first line systemic therapies for HNSCC (SEQ-HN)
    Meeting Abstract

    Haddad, R. I.; Harrington, K. J.; Licitra, L. F.; Psyrri, A.; Saba, N. F.; Rajicic, N.; Balsara, B.; Kurman, M. R.; Scholz, C. R.; Gualberto, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase I/II study of HB-201, an arenavirus-based cancer immunotherapy, alone, or in combination with anti-PD-1 in patients with HPV16(+) cancers
    Meeting Abstract

    Burman, B.; Niu, J.; Leidner, R. S.; Wang, D.; Richardson, D. L.; Iacobucci, C.; Hwang, A.; Qing, X.; Matushansky, I.; Zamarin, D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (MBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIS)
    Meeting Abstract

    Lewis, K.; Peris, K.; Sekulic, A.; Stratigos, A.; Dunn, L.; Eroglu, Z.; Chang, A. L.; Migden, M.; Li, S.; Mohan, K.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Pai, S.; Adkins, D.; Wirth, L.; Chung, C.; Gibson, M.; Sukari, A.; Worden, F.; Colevas, D.; Saba, N.; Burtness, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save